Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Leukemia

  Free Subscription


Articles published in Am J Hematol

Retrieve available abstracts of 145 articles:
HTML format



Single Articles


    November 2022
  1. RADICH J
    Allogeneic transplantation for chronic myeloid leukemia: I'm not dead yet!
    Am J Hematol. 2022 Nov 24. doi: 10.1002/ajh.26790.
    PubMed    


  2. WIECZOREK M, Labopin M, Castagna L, Brissot E, et al
    Post-transplant Cyclophosphamide in Acute Leukemia Patients Receiving more than 5/10 HLA-Mismatched Allogeneic Hematopoietic Cell Transplantation from Related Donors: a Study on behalf of the ALWP of the EBMT.
    Am J Hematol. 2022 Nov 18. doi: 10.1002/ajh.26782.
    PubMed    


  3. LEVI S, Bronstein Y, Goldschmidt N, Morabito F, et al
    Efficacy of front-line ibrutinib versus fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: A retrospective multicenter "Real-World" study.
    Am J Hematol. 2022 Nov 8. doi: 10.1002/ajh.26779.
    PubMed    


  4. WOYACH JA
    Management of relapsed/refractory Chronic Lymphocytic Leukemia.
    Am J Hematol. 2022;97 Suppl 2:S11-S18.
    PubMed     Abstract available


  5. ARONSON JH, Skanland SS, Roeker LE, Thompson MC, et al
    Approach to a patient with "double refractory" chronic lymphocytic leukemia: "Double, double toil and trouble" (Shakespeare).
    Am J Hematol. 2022;97 Suppl 2:S19-S25.
    PubMed     Abstract available


  6. KUTSCH N, Fink AM, Fischer K
    Management of front line chronic lymphocytic leukemia.
    Am J Hematol. 2022;97 Suppl 2:S3-S10.
    PubMed     Abstract available


  7. CHIUSOLO P, Marchetti C, Rossi M, Minnella G, et al
    A common pattern of somatic mutations in t-MDS/AML of patients treated with PARP inhibitors for metastatic ovarian cancer.
    Am J Hematol. 2022;97:E400-E403.
    PubMed    


  8. MCVINNIE K, Innes A, Nadal-Melsio E, Atta M, et al
    A case of chronic neutrophilic leukemia and multiple myeloma showing the benefits of lenalidomide and cyclophosphamide therapy in treating both conditions.
    Am J Hematol. 2022;97:1491-1494.
    PubMed    


    October 2022
  9. ALDULESCU M, Leuer K, Jennings LJ, Yap KL, et al
    Lineage switch from acute myeloid leukemia to B-lymphoblastic lymphoma with acquired PIK3R1 loss-of-function mutation.
    Am J Hematol. 2022 Oct 26. doi: 10.1002/ajh.26770.
    PubMed    


  10. CHALANDON Y, Sbianchi G, Gras L, Koster L, et al
    Allogeneic hematopoietic cell transplantation in patients with chronic phase chronic myeloid leukemia in the era of third generation tyrosine kinase inhibitors: A retrospective study by the chronic malignancies working party of the EBMT.
    Am J Hematol. 2022 Oct 20. doi: 10.1002/ajh.26764.
    PubMed     Abstract available


  11. STAHL M, Derkach A, Farnoud N, Bewersdorf JP, et al
    Molecular predictors of immunophenotypic measurable residual disease clearance in acute myeloid leukemia.
    Am J Hematol. 2022 Oct 17. doi: 10.1002/ajh.26757.
    PubMed     Abstract available


  12. WANG Q, Cai WZ, Wang QR, Zhu MQ, et al
    Integrative genomic and transcriptomic profiling reveals distinct molecular subsets in adult mixed phenotype acute leukemia.
    Am J Hematol. 2022 Oct 11. doi: 10.1002/ajh.26758.
    PubMed     Abstract available


  13. KITTAI AS, Huang Y, Beckwith KA, Bhat SA, et al
    Patient characteristics that predict Richter's transformation in patients with chronic lymphocytic leukemia treated with ibrutinib.
    Am J Hematol. 2022 Oct 10. doi: 10.1002/ajh.26755.
    PubMed     Abstract available


  14. LANZA L, Koroveshi B, Barducchi F, Lorenzo A, et al
    A new diagnosis of monoclonal B-cell lymphocytosis with cytoplasmic inclusions in a patient with COVID-19.
    Am J Hematol. 2022;97:1372-1373.
    PubMed    



  15. Abstracts from the 2022 Lymphoma, Leukemia and Myeloma Congress October 18-22, 2022.
    Am J Hematol. 2022;97 Suppl 3:S3-S40.
    PubMed    


    September 2022
  16. RIVERA D, Kim K, Kanagal-Shamanna R, Borthakur G, et al
    Implications of RAS Mutational Status in Subsets of Patients with Newly Diagnosed Acute Myeloid Leukemia Across Therapy Subtypes.
    Am J Hematol. 2022 Sep 18. doi: 10.1002/ajh.26731.
    PubMed     Abstract available


  17. ZIPPER R, Fong V, Toker M, Reddy N, et al
    Neutrophilic Eccrine Hidradenitis in a pediatric patient with Acute Myeloid Leukemia.
    Am J Hematol. 2022 Sep 16. doi: 10.1002/ajh.26733.
    PubMed    


  18. WRIGHT MF, Pozdnyakova O, Hasserjian RP, Aggarwal N, et al
    Secondary-type mutations do not impact prognosis in acute myelogenous leukemia AML with mutated NPM1.
    Am J Hematol. 2022 Sep 15. doi: 10.1002/ajh.26730.
    PubMed    


  19. VENUGOPAL S, DiNardo CD, Loghavi S, Qiao W, et al
    Differential Prognostic Impact of RUNX1 Mutations According to Frontline Therapy in Patients with Acute Myeloid Leukemia.
    Am J Hematol. 2022 Sep 10. doi: 10.1002/ajh.26724.
    PubMed     Abstract available


  20. LEE BJ, Griffin SP, Doh J, Chan A, et al
    CD19-Directed Immunotherapy Use in KMT2A-Rearranged Acute Leukemia: A Case Report and Literature Review of Increased Lymphoid to Myeloid Lineage Switch.
    Am J Hematol. 2022 Sep 3. doi: 10.1002/ajh.26713.
    PubMed    


  21. FALINI B
    Acute myeloid leukemia risk models: Where do we stand?
    Am J Hematol. 2022;97:1124-1126.
    PubMed    


    August 2022
  22. PRATZ KW, DiNardo CD, Selleslag D, Li J, et al
    Postremission cytopenia management in patients with AML treated with venetoclax and azacitidine in VIALE-A.
    Am J Hematol. 2022 Aug 30. doi: 10.1002/ajh.26692.
    PubMed    


  23. JONAS BA, DiNardo C, Fracchiolla N, Pristupa A, et al
    Use of CYP3Ai and impact on outcomes in patients with AML treated with venetoclax plus azacitidine in the VIALE-A study.
    Am J Hematol. 2022 Aug 28. doi: 10.1002/ajh.26707.
    PubMed    


  24. BORTHAKUR G, Ravandi F, Patel K, Wang X, et al
    Retrospective comparison of survival and responses to Fludarabine, Cytarabine, GCSF (FLAG) in combination with gemtuzumab ozogamicin (GO) or Idarubicin (IDA) in patients with newly diagnosed core binding factor (CBF) acute myelogenous leukemia: MD And
    Am J Hematol. 2022 Aug 26. doi: 10.1002/ajh.26700.
    PubMed     Abstract available


  25. SHORT NJ, Macaron W, Kadia T, Dinardo C, et al
    Clinical outcomes and impact of therapeutic intervention in patients with acute myeloid leukemia who experience MRD recurrence following MRD-negative remission.
    Am J Hematol. 2022 Aug 24. doi: 10.1002/ajh.26698.
    PubMed    


  26. TEFFERI A, Begna KH, McCullough KB
    Tyrosine kinase inhibitors dosing for chronic phase chronic myeloid leukemia: The case for starting low with dasatinib (50 mg/day) and ponatinib (15 mg/day).
    Am J Hematol. 2022 Aug 22. doi: 10.1002/ajh.26695.
    PubMed    


  27. LACHOWIEZ CA, Reville PK, Kantarjian H, Jabbour E, et al
    Contemporary outcomes in IDH-mutated AML: The impact of co-occurring NPM1 mutations and venetoclax-based treatment.
    Am J Hematol. 2022 Aug 22. doi: 10.1002/ajh.26694.
    PubMed     Abstract available


  28. JABBOUR E, Sasaki K, Haddad FG, Issa GC, et al
    Low-dose dasatinib 50 mg/day versus standard-dose dasatinib 100 mg/day as frontline therapy in chronic myeloid leukemia in chronic phase: A propensity score analysis.
    Am J Hematol. 2022 Aug 13. doi: 10.1002/ajh.26689.
    PubMed     Abstract available


  29. KANTARJIAN HM, Jabbour E, Deininger M, Abruzzese E, et al
    Ponatinib after failure of second-generation tyrosine kinase inhibitor in resistant chronic-phase chronic myeloid leukemia.
    Am J Hematol. 2022 Aug 12. doi: 10.1002/ajh.26686.
    PubMed     Abstract available


  30. SHAH MV, Chhetri R, Dholakia R, Kok CH, et al
    Outcomes following venetoclax-based treatment in therapy-related myeloid neoplasms.
    Am J Hematol. 2022;97:1013-1022.
    PubMed     Abstract available


    July 2022
  31. SHORT NJ, Kantarjian H
    Hypomethylating Agents for the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia: Past Discoveries and Future Directions.
    Am J Hematol. 2022 Jul 24. doi: 10.1002/ajh.26667.
    PubMed     Abstract available


  32. HERRMANN L, Bischof L, Backhaus D, Brauer D, et al
    Outcome prediction by the knowledge bank approach in acute myeloid leukemia patients undergoing allogeneic stem cell transplantation.
    Am J Hematol. 2022 Jul 8. doi: 10.1002/ajh.26653.
    PubMed    


  33. PETER B, Eisenwort G, Sadovnik I, Bauer K, et al
    BRD4 Degradation Blocks Expression of MYC and Multiple Forms of Stem Cell Resistance in Ph(+) Chronic Myeloid Leukemia.
    Am J Hematol. 2022 Jul 6. doi: 10.1002/ajh.26650.
    PubMed     Abstract available


  34. BADAR T, Atallah E, Shallis RM, Goldberg AD, et al
    Outcomes of TP53-mutated AML with evolving frontline therapies: Impact of allogeneic stem cell transplantation on survival.
    Am J Hematol. 2022;97:E232-E235.
    PubMed    


    June 2022
  35. ALCAZER V, Bonaventura P, Tonon L, Michel E, et al
    HERVs characterize normal and leukemia stem cells and represent a source of shared epitopes for cancer immunotherapy.
    Am J Hematol. 2022 Jun 27. doi: 10.1002/ajh.26647.
    PubMed     Abstract available


  36. NICHOLS ED, Jammal N, Chew S, Bryan J, et al
    Real-life incidence of thrombotic events in leukemia patients treated with ponatinib.
    Am J Hematol. 2022 Jun 27. doi: 10.1002/ajh.26645.
    PubMed    


  37. JABBOUR E, Kantarjian H
    Chronic Myeloid Leukemia: 2022 Update on Diagnosis, Therapy and Monitoring.
    Am J Hematol. 2022 Jun 25. doi: 10.1002/ajh.26642.
    PubMed     Abstract available


  38. DHOPESHWARKAR N, Yang W, Hennessy S, Rhodes JM, et al
    Rate of major bleeding with ibrutinib versus bendamustine-rituximab in chronic lymphocytic leukemia: a population-based cohort study.
    Am J Hematol. 2022 Jun 17. doi: 10.1002/ajh.26632.
    PubMed    


  39. JABBOUR EJ, Short NJ, Jain N, Jammal N, et al
    Blinatumomab Is Associated with Favorable Outcomes in Patients With B-cell Lineage Acute Lymphoblastic Leukemia and Positive Measurable Residual Disease at a Threshold of 10(-4) and Higher.
    Am J Hematol. 2022 Jun 17. doi: 10.1002/ajh.26634.
    PubMed     Abstract available


  40. TEFFERI A, Gangat N, Al-Kali A, Alkhateeb H, et al
    A dynamic 3-factor survival model for acute myeloid leukemia that accounts for response to induction chemotherapy.
    Am J Hematol. 2022 Jun 15. doi: 10.1002/ajh.26630.
    PubMed     Abstract available


  41. BARON F, Labopin M, Tischer J, Ciceri F, et al
    Human leukocyte antigen-haploidentical transplantation for relapsed/refractory acute myeloid leukemia: Better leukemia-free survival with bone marrow than with peripheral blood stem cells in patients >/=55 years of age.
    Am J Hematol. 2022 Jun 13. doi: 10.1002/ajh.26627.
    PubMed     Abstract available


    May 2022
  42. PAUL S, Kantarjian H, Sasaki K, Marx K, et al
    Intrathecal Prophylaxis with 12 Versus 8 Administrations Reduces the Incidence of Central Nervous System Relapse in Patients with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia.
    Am J Hematol. 2022 May 28. doi: 10.1002/ajh.26622.
    PubMed    


  43. BEELEN DW, Stelljes M, Remenyi P, Wagner-Drouet EM, et al
    Treosulfan Compared with Reduced-Intensity Busulfan Improves Allogeneic Hematopoietic Cell Transplantation Outcomes of Older Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients: Final Analysis of a Prospective Randomized Trial.
    Am J Hematol. 2022 May 26. doi: 10.1002/ajh.26620.
    PubMed     Abstract available


  44. VABRE C, Zelmat Y, Gauthier M, Pajiep M, et al
    Incident users of tyrosine kinase inhibitors in chronic myeloid leukemia patients: analysis of anticancer treatment trajectories - A French population-based study using the French national health data system.
    Am J Hematol. 2022 May 26. doi: 10.1002/ajh.26621.
    PubMed    


  45. GAMBACORTI-PASSERINI C, Nicolini FE, Larson RA, Aroldi A, et al
    Caution in using second generation tyrosine kinase inhibitor, especially for first line therapy of chronic myeloid leukemia.
    Am J Hematol. 2022 May 23. doi: 10.1002/ajh.26618.
    PubMed    


  46. DINARDO CD, Lachowiez CA, Takahashi K, Loghavi S, et al
    Venetoclax Combined with FLAG-IDA Induction and Consolidation in Newly Diagnosed Acute Myeloid Leukemia.
    Am J Hematol. 2022 May 18. doi: 10.1002/ajh.26601.
    PubMed     Abstract available


  47. JONAS BA, Wei AH, Recher C, DiNardo CD, et al
    Timing of response with venetoclax combination treatment in patients with newly diagnosed acute myeloid leukemia.
    Am J Hematol. 2022 May 14. doi: 10.1002/ajh.26600.
    PubMed    


  48. CHERNG HJ, Khwaja R, Kanagal-Shamanna R, Tang G, et al
    TP53-altered chronic lymphocytic leukemia treated with firstline Bruton's tyrosine kinase inhibitor-based therapy: A retrospective analysis.
    Am J Hematol. 2022 May 14. doi: 10.1002/ajh.26595.
    PubMed     Abstract available


  49. GOTTLIEB DJ, Sutrave G, Jiang W, Avdic S, et al
    Combining CD34+ stem cell selection with prophylactic pathogen and leukemia directed T-cell immunotherapy to simultaneously reduce graft versus host disease, infection and leukemia recurrence after allogeneic stem cell transplant.
    Am J Hematol. 2022 May 12. doi: 10.1002/ajh.26594.
    PubMed     Abstract available


  50. SINGH A, Al-Kali A, Begna KH, Litzow MR, et al
    Midostaurin therapy for advanced systemic mastocytosis: Mayo Clinic experience in 33 consecutive cases.
    Am J Hematol. 2022;97:630-637.
    PubMed     Abstract available


  51. WANG J, Zhang X, Zhou Z, Liu Y, et al
    A Novel Adoptive Synthetic TCR and Antigen Receptor (STAR) T-Cell Therapy for B-Cell Acute Lymphoblastic Leukemia.
    Am J Hematol. 2022 May 1. doi: 10.1002/ajh.26586.
    PubMed     Abstract available


  52. GORDON MJ, Ferrajoli A
    Unusual complications in the management of chronic lymphocytic leukemia.
    Am J Hematol. 2022 May 1. doi: 10.1002/ajh.26585.
    PubMed     Abstract available


    April 2022
  53. PEREZ-CARRETERO C, Hernandez-Sanchez M, Gonzalez T, Quijada-Alamo M, et al
    TRAF3 alterations are frequent in del-3'IGH chronic lymphocytic leukemia patients and define a specific subgroup with adverse clinical features.
    Am J Hematol. 2022 Apr 26. doi: 10.1002/ajh.26578.
    PubMed     Abstract available


  54. KIM K, Konopleva M, DiNardo CD, Borthakur G, et al
    Urgent cytoreduction for newly diagnosed acute myeloid leukemia patients allows acquisition of pretreatment genomic data and enrollment on investigational clinical trials.
    Am J Hematol. 2022 Apr 12. doi: 10.1002/ajh.26572.
    PubMed     Abstract available


  55. TANG B, Lee JB, Cheng S, Pan T, et al
    Allogeneic double-negative T cell therapy for relapsed acute myeloid leukemia patients post allogeneic hematopoietic stem cell transplantation: A first-in-human phase I study.
    Am J Hematol. 2022 Apr 6. doi: 10.1002/ajh.26564.
    PubMed    


  56. SASAKI K, Ravandi F, Kadia T, DiNardo C, et al
    Prediction of Survival with Intensive Chemotherapy in Acute Myeloid Leukemia.
    Am J Hematol. 2022 Apr 5. doi: 10.1002/ajh.26557.
    PubMed     Abstract available


  57. INZOLI E, Aroldi A, Piazza R, Gambacorti-Passerini C, et al
    Tyrosine Kinase Inhibitor discontinuation in Chronic Myeloid Leukemia: eligibility criteria and predictors of success.
    Am J Hematol. 2022 Apr 5. doi: 10.1002/ajh.26556.
    PubMed     Abstract available


  58. LARSSON K, Soderling J, Hoglund M, Glimelius I, et al
    Cardiovascular disease in patients with chronic lymphocytic leukemia. A Swedish nationwide register study with matched comparators.
    Am J Hematol. 2022 Apr 5. doi: 10.1002/ajh.26558.
    PubMed    


  59. MCLAUGHLIN N, Ruan G, Day CN, Harmsen WS, et al
    A population-based study of acute panmyelosis with myelofibrosis in the United States: 2004-2015.
    Am J Hematol. 2022;97:E144-E147.
    PubMed    


    March 2022
  60. HADDAD FG, Sasaki K, Issa GC, Garcia-Manero G, et al
    Treatment-Free Remission in Patients with Chronic Myeloid Leukemia Following the Discontinuation of Tyrosine Kinase Inhibitors.
    Am J Hematol. 2022 Mar 31. doi: 10.1002/ajh.26550.
    PubMed     Abstract available


  61. COOK L, Al-Yousuf H, Mohamedbhai S, Bain BJ, et al
    Hyposplenism in adult T-cell leukemia/lymphoma.
    Am J Hematol. 2022 Mar 26. doi: 10.1002/ajh.26547.
    PubMed    


  62. TORELLI GF, Chiaretti S, Peragine N, Barberi W, et al
    Repeated infusions of escalating doses of expanded and activated autologous natural killer cells in minimal residual disease-positive Ph+ acute lymphoblastic leukemia patients. A GIMEMA phase 1 trial.
    Am J Hematol. 2022 Mar 22. doi: 10.1002/ajh.26537.
    PubMed    


  63. KRAKOW EF, Walter RB, Nathe JM, Perez T, et al
    Intensive Chemotherapy for Acute Myeloid Leukemia Relapse after Allogeneic Hematopoietic Cell Transplantation.
    Am J Hematol. 2022 Mar 18. doi: 10.1002/ajh.26540.
    PubMed    


  64. SMITH AC, Maze D, Xia D, Capo-Chichi JM, et al
    A t(6;14;9)(p22;q22;q34) Three-Way Translocation: Description of a Cytogenetically Visible Variant t(6;9) in Acute Myeloid Leukemia.
    Am J Hematol. 2022 Mar 16. doi: 10.1002/ajh.26534.
    PubMed    


  65. GALLANT RE, Arroyo K, Bracci PM, Li S, et al
    Clinical characteristics of cytomegalovirus-positive pediatric acute lymphoblastic leukemia at diagnosis.
    Am J Hematol. 2022 Mar 14. doi: 10.1002/ajh.26528.
    PubMed    


  66. SHORT NJ, Macaron W, Konopleva M, Ravandi F, et al
    Dismal outcomes of patients with relapsed/refractory Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia after failure of both inotuzumab ozogamicin and blinatumomab.
    Am J Hematol. 2022 Mar 10. doi: 10.1002/ajh.26526.
    PubMed    


  67. KENNEDY VE, Hui G, Azenkot T, Gaut D, et al
    Outcomes of Allogeneic Transplantation after Hypomethylating Agents with Venetoclax in Acute Myeloid Leukemia.
    Am J Hematol. 2022 Mar 9. doi: 10.1002/ajh.26524.
    PubMed    


  68. ORTIZ-MALDONADO V, Alonso-Saladrigues A, Espanol-Rego M, Martinez-Cibrian N, et al
    Results of ARI-0001 CART19 cell therapy in patients with relapsed/refractory CD19-positive acute lymphoblastic leukemia with isolated extramedullary disease.
    Am J Hematol. 2022 Mar 7. doi: 10.1002/ajh.26519.
    PubMed     Abstract available


    February 2022
  69. MOSHREF RAZAVI H, Yu R
    Myeloid neoplasm with PDGFRB rearrangement, presenting as systemic mastocytosis-chronic eosinophilic leukemia.
    Am J Hematol. 2022 Feb 21. doi: 10.1002/ajh.26505.
    PubMed    


  70. POMMERT L, Schafer ES, Malvar J, Gossai N, et al
    Decitabine and Vorinostat with FLAG Chemotherapy in Pediatric Relapsed/Refractory AML: Report from the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium.
    Am J Hematol. 2022 Feb 18. doi: 10.1002/ajh.26510.
    PubMed     Abstract available


  71. ARBER DA, Hasserjian RP, Orazi A, Mathews V, et al
    Classification of myeloid neoplasms/acute leukemia: global perspectives and the International Consensus Classification (ICC) approach.
    Am J Hematol. 2022 Feb 18. doi: 10.1002/ajh.26503.
    PubMed    


  72. BALL S, Jain AG, Aguirre LE, Al Ali N, et al
    Hypomethylating Agent and Venetoclax in Patients with Chronic Myelomonocytic Leukemia: Is the Combination Indeed Better?
    Am J Hematol. 2022 Feb 18. doi: 10.1002/ajh.26504.
    PubMed    


  73. SHI M, Li L, Wang S, Cheng H, et al
    Safety and efficacy of a humanized CD19 chimeric antigen receptor T cells for relapsed/refractory acute lymphoblastic leukemia.
    Am J Hematol. 2022 Feb 18. doi: 10.1002/ajh.26506.
    PubMed     Abstract available


  74. MOLICA S, Giannarelli D, Visentin A, Reda G, et al
    Prediction of outcomes in chronic lymphocytic leukemia patients treated with ibrutinib: Validation of current prognostic models and development of a simplified three-factor model.
    Am J Hematol. 2022 Feb 16. doi: 10.1002/ajh.26502.
    PubMed    


  75. SENAPATI J, Shoukier M, Garcia-Manero G, Wang X, et al
    Activity of Decitabine as Maintenance Therapy in Core Binding Factor Acute Myeloid Leukemia.
    Am J Hematol. 2022 Feb 12. doi: 10.1002/ajh.26496.
    PubMed     Abstract available


  76. POURHASSAN H, Yang D, Afkhami M, Pillai R, et al
    High prevalence and inferior long-term outcomes for TP53 mutations in therapy-related acute lymphoblastic leukemia.
    Am J Hematol. 2022 Feb 7. doi: 10.1002/ajh.26490.
    PubMed    


  77. RACK K, De Bie J, Ameye G, Gielen O, et al
    Optimizing the Diagnostic Workflow for Acute Lymphoblastic Leukemia by Optical Genome Mapping.
    Am J Hematol. 2022 Feb 4. doi: 10.1002/ajh.26487.
    PubMed     Abstract available


  78. ALLSUP DJ, Craig Z, Cairns D, Howard D, et al
    Long-term follow-up of 415 patients with chronic lymphocytic leukemia treated with fludarabine and cyclophosphamide-based chemoimmunotherapy in the frontline ADMIRE and ARCTIC trials: A comprehensive assessment of prognostic factors.
    Am J Hematol. 2022 Feb 2. doi: 10.1002/ajh.26483.
    PubMed    


  79. UJJANI C, Greninger AL, Shadman M, Hill JA, et al
    Heterologous SARS-CoV-2 vaccinations in patients with B-cell lymphoid malignancies.
    Am J Hematol. 2022;97:E67-E69.
    PubMed    


  80. GAO F, Gao Y, Luo Y, Yu J, et al
    Venetoclax plus hypomethylating agent for the salvage treatment of relapsing myeloid malignancies after hematopoietic stem cell transplantation: A multicenter retrospective study on behalf of the Zhejiang Cooperative Group for Blood and Marrow Transpl
    Am J Hematol. 2022;97:E44-E47.
    PubMed    


  81. KUNO M, Yamasaki S, Fujii N, Ishida Y, et al
    Characterization of myeloid neoplasms following allogeneic hematopoietic cell transplantation.
    Am J Hematol. 2022;97:185-193.
    PubMed     Abstract available


    January 2022
  82. SZUBER N, Elliott M, Tefferi A
    Chronic neutrophilic leukemia: 2022 update on diagnosis, genomic landscape, prognosis, and management.
    Am J Hematol. 2022 Jan 28. doi: 10.1002/ajh.26481.
    PubMed     Abstract available


  83. LAZARIAN G, Theves F, Hormi M, Letestu R, et al
    TP53 mutations at codon 234 are associated with chlorambucil treatment in chronic lymphocytic leukemia.
    Am J Hematol. 2022 Jan 26. doi: 10.1002/ajh.26479.
    PubMed    


  84. IJURKO C, Gonzalez-Garcia N, Galindo-Villardon P, Hernandez-Hernandez A, et al
    A 29-gene signature associated with NOX2 discriminates acute myeloid leukemia prognosis and survival.
    Am J Hematol. 2022 Jan 24. doi: 10.1002/ajh.26477.
    PubMed     Abstract available


  85. DORFMAN DM, Pinkus GS
    A case of peripheral T-cell lymphoma, NOS mimicking acute monocytic leukemia.
    Am J Hematol. 2022 Jan 22. doi: 10.1002/ajh.26476.
    PubMed    


  86. ROSSI M, Nizzoli ME, Galli A, Roncoroni E, et al
    Sequential next generation sequencing analysis in homogeneously treated low risk NPM1-mutated acute myeloid leukemia with an adverse clinical outcome.
    Am J Hematol. 2022 Jan 18. doi: 10.1002/ajh.26469.
    PubMed    


  87. DAHLEN T, Edgren G, Ljungman P, Flygt H, et al
    Adverse outcomes in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: Follow-up of patients diagnosed 2002-2017 in a complete coverage and nationwide agnostic register study.
    Am J Hematol. 2022 Jan 11. doi: 10.1002/ajh.26463.
    PubMed     Abstract available


  88. JELLOUL FZ, Yang R, Wang P, Garces S, et al
    Non-Coding NOTCH1 Mutations in Chronic Lymphocytic Leukemia Negatively Impact Prognosis.
    Am J Hematol. 2022 Jan 6. doi: 10.1002/ajh.26457.
    PubMed    


  89. PATNAIK MM, Tefferi A
    Chronic Myelomonocytic Leukemia: 2022 Update on Diagnosis, Risk Stratification and Management.
    Am J Hematol. 2022 Jan 5. doi: 10.1002/ajh.26455.
    PubMed     Abstract available


  90. REVILLE PK, Sasaki K, Kantarjian HM, Daver NG, et al
    Improved outcomes among newly diagnosed patients with FMS-like tyrosine kinase 3 internal tandem duplication mutated acute myeloid leukemia treated with contemporary therapy: Revisiting the European LeukemiaNet adverse risk classification.
    Am J Hematol. 2022 Jan 3. doi: 10.1002/ajh.26451.
    PubMed     Abstract available


  91. NUMAN Y, Abdel Rahman Z, Grenet J, Boisclair S, et al
    Gilteritinib clinical activity in relapsed/refractory FLT3 mutated acute myeloid leukemia previously treated with FLT3 inhibitors.
    Am J Hematol. 2022 Jan 3. doi: 10.1002/ajh.26447.
    PubMed     Abstract available


  92. NAGLER A, Labopin M, Craddock C, Socie G, et al
    Cytogenetic risk classification maintains its prognostic significance in transplanted FLT3-ITD mutated acute myeloid leukemia patients: On behalf of the acute leukemia working party/European society of blood and marrow transplantation.
    Am J Hematol. 2022 Jan 3. doi: 10.1002/ajh.26442.
    PubMed     Abstract available


  93. RIBEIL JA
    Primary myelofibrosis in untreated sickle cell disease: Are adult patients at higher risk for developing hematological myeloid neoplasms?
    Am J Hematol. 2022;97:4-6.
    PubMed    


    December 2021
  94. DAVIDS MS, Shadman M, Parikh SA, Ujjani C, et al
    A multicenter, retrospective study of accelerated venetoclax ramp-up in patients with relapsed/refractory chronic lymphocytic leukemia.
    Am J Hematol. 2021 Dec 20. doi: 10.1002/ajh.26444.
    PubMed    


  95. VISENTIN A, Mauro FR, Cibien F, Vitale C, et al
    Continuous treatment with Ibrutinib in 100 untreated patients with TP53 disrupted chronic lymphocytic leukemia: A real-life campus CLL study.
    Am J Hematol. 2021 Dec 14. doi: 10.1002/ajh.26437.
    PubMed    


  96. SEGOT A, Stalder G, de Leval L, Solly F, et al
    Venetoclax combined with FLAG-based chemotherapy induces an early and deep response in mixed-phenotype-acute leukemia.
    Am J Hematol. 2021 Dec 14. doi: 10.1002/ajh.26436.
    PubMed    


  97. FORTES BH, Dalvin LA, Hogan WJ, Patnaik MM, et al
    Isolated T-cell acute lymphoblastic leukemic optic disc infiltration.
    Am J Hematol. 2021;96:1717-1718.
    PubMed    


    November 2021
  98. SANTOS FM, Ghelfond G, Seguro FS, Abdo ANR, et al
    Analyzing the impact of pregnancy on the outcomes of childbearing age women with chronic myeloid leukemia.
    Am J Hematol. 2021 Nov 25. doi: 10.1002/ajh.26424.
    PubMed    


  99. POPOVIC R, Dunbar F, Lu C, Robinson K, et al
    Identification of recurrent genomic alterations in the apoptotic machinery in chronic lymphocytic leukemia patients treated with venetoclax monotherapy.
    Am J Hematol. 2021 Nov 14. doi: 10.1002/ajh.26411.
    PubMed    


  100. CHO BS, Min GJ, Park SS, Yoon SY, et al
    Low-dose thymoglobulin for prevention of chronic graft-versus-host disease in transplantation from an HLA-matched sibling donor.
    Am J Hematol. 2021;96:1441-1449.
    PubMed     Abstract available


    October 2021
  101. SASAKI K, Kadia T, Begna K, DiNardo CD, et al
    Prediction of Early (4-week) Mortality in Acute Myeloid Leukemia with Intensive Chemotherapy.
    Am J Hematol. 2021 Oct 30. doi: 10.1002/ajh.26395.
    PubMed     Abstract available


  102. TROUSSARD X, Maitre E, Cornet E
    Hairy cell leukemia 2022: Update on diagnosis, risk-stratification, and treatment.
    Am J Hematol. 2021 Oct 28. doi: 10.1002/ajh.26390.
    PubMed     Abstract available


  103. MUCHTAR E, Koehler AB, Johnson MJ, Rabe KG, et al
    Humoral and cellular immune responses to recombinant herpes zoster vaccine in patients with chronic lymphocytic leukemia and monoclonal B cell lymphocytosis.
    Am J Hematol. 2021 Oct 26. doi: 10.1002/ajh.26388.
    PubMed     Abstract available


  104. ZHANG Y, Li X, Weng X, Shen Y, et al
    Optimization of idarubicin and cytarabine induction regimen with homoharringtonine for newly diagnosed acute myeloid leukemia patients based on the peripheral blast clearance rate: a single-arm, phase 2 trial (RJ-AML 2014).
    Am J Hematol. 2021 Oct 23. doi: 10.1002/ajh.26386.
    PubMed     Abstract available


  105. HALLEK M, Al-Sawaf O
    Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures.
    Am J Hematol. 2021 Oct 9. doi: 10.1002/ajh.26367.
    PubMed     Abstract available


  106. HERZOG TZARFATI K, Gutwein O, Apel A, Rahimi-Levene N, et al
    BNT162b2 COVID-19 vaccine is significantly less effective in patients with hematologic malignancies.
    Am J Hematol. 2021;96:1195-1203.
    PubMed     Abstract available


  107. GRIMM J, Jentzsch M, Bill M, Backhaus D, et al
    Clinical implications of SRSF2 mutations in AML patients undergoing allogeneic stem cell transplantation.
    Am J Hematol. 2021;96:1287-1294.
    PubMed     Abstract available


    September 2021
  108. FURSTENAU M, Giza A, Stumpf T, Robrecht S, et al
    Second primary malignancies in treated and untreated patients with chronic lymphocytic leukemia.
    Am J Hematol. 2021 Sep 30. doi: 10.1002/ajh.26363.
    PubMed    


    August 2021
  109. SALIBA AN, Litzow MR, Gangat N, Al-Kali A, et al
    Outcomes of Venetoclax-Based Therapy in Chronic Phase and Blast Transformed Chronic Myelomonocytic Leukemia.
    Am J Hematol. 2021 Aug 24. doi: 10.1002/ajh.26334.
    PubMed    


  110. ZHOU B, Chu X, Tian H, Liu T, et al
    The Clinical Outcomes and Genomic Landscapes of Acute Lymphoblastic Leukemia Patients with E2A-PBX1: A 10-year Retrospective Study.
    Am J Hematol. 2021 Aug 18. doi: 10.1002/ajh.26324.
    PubMed     Abstract available


  111. ZHANG M, Xiao H, Shi J, Tan Y, et al
    Improved survival for young acute leukemia patients following a new donor hierarchy for allogeneic hematopoietic stem cell transplantation: a phase III randomized controlled study.
    Am J Hematol. 2021 Aug 9. doi: 10.1002/ajh.26317.
    PubMed     Abstract available


  112. ALWASH Y, Khoury JD, Tashakori M, Kanagal-Shamanna R, et al
    Development of TP53 Mutations Over the Course of Therapy for Acute Myeloid Leukemia.
    Am J Hematol. 2021 Aug 5. doi: 10.1002/ajh.26314.
    PubMed     Abstract available


  113. CHEN Z, Song J, Wang W, Bai J, et al
    A novel 4-mRNA signature predicts the overall survival in acute myeloid leukemia.
    Am J Hematol. 2021 Aug 2. doi: 10.1002/ajh.26309.
    PubMed     Abstract available


    July 2021
  114. VARETTONI M, Orlandi E, Zibellini S, Rossi M, et al
    Prognostic impact of somatic mutations on time to first treatment: results of targeted next-generation sequencing in 211 patients with early stage chronic lymphocytic leukemia.
    Am J Hematol. 2021 Jul 30. doi: 10.1002/ajh.26302.
    PubMed    


  115. KUSNE Y, Lasho T, Mangaonkar A, Tefferi A, et al
    Remarkable stability in clonal hematopoiesis involving leukemia-driver genes in patients without underlying myeloid neoplasms.
    Am J Hematol. 2021 Jul 21. doi: 10.1002/ajh.26297.
    PubMed    


  116. BROCCOLI A, Argnani L, Nanni L, Terragna C, et al
    The treatment of hairy cell leukemia with a focus on long lasting responses to cladribine: a thirty-year experience.
    Am J Hematol. 2021 Jul 10. doi: 10.1002/ajh.26287.
    PubMed     Abstract available


  117. GANGAT N, Guglielmelli P, Szuber N, Begna KH, et al
    Venetoclax with azacitidine or decitabine in blast-phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases.
    Am J Hematol. 2021;96:781-789.
    PubMed     Abstract available


  118. HAYDU JE, Flamand Y, Vedula RS, Versluis J, et al
    Pretreatment clinical and genetic factors predict early post-treatment mortality in fit AML patients following induction.
    Am J Hematol. 2021;96:E259-E262.
    PubMed    


  119. JENTZSCH M, Grimm J, Bill M, Brauer D, et al
    Clinical value of the measurable residual disease status within the ELN2017 risk groups in AML patients undergoing allogeneic stem cell transplantation.
    Am J Hematol. 2021;96:E237-E239.
    PubMed    


  120. JOSHI SK, Sharzehi S, Pittsenbarger J, Bottomly D, et al
    A noncanonical FLT3 gatekeeper mutation disrupts gilteritinib binding and confers resistance.
    Am J Hematol. 2021;96:E226-E229.
    PubMed    


  121. OZGA M, Blachly J, Eisfeld AK, Grieselhuber N, et al
    Type of prior genotoxic insult determines the genomic characteristics of therapy-related myeloid neoplasms.
    Am J Hematol. 2021;96:E223-E225.
    PubMed    


    June 2021
  122. JABBOUR E, Patel K, Jain N, Duose D, et al
    Impact of Philadelphia chromosome-like alterations on efficacy and safety of blinatumomab in adults with relapsed/refractory acute lymphoblastic leukemia: a post hoc analysis from the phase 3 TOWER study.
    Am J Hematol. 2021 Jun 23. doi: 10.1002/ajh.26281.
    PubMed     Abstract available


  123. LAZARIAN G, Munger M, Quinquenel A, Dilhuydy MS, et al
    Clinical and biological characteristics of leukemia cutis in Chronic Lymphocytic Leukemia: a study of the French Innovative Leukemia Organization (FILO).
    Am J Hematol. 2021 Jun 21. doi: 10.1002/ajh.26274.
    PubMed    


  124. MOIGNET A, Pastoret C, Cartron G, Coppo P, et al
    Ruxolitinib for refractory large granular lymphocyte leukemia.
    Am J Hematol. 2021 Jun 16. doi: 10.1002/ajh.26275.
    PubMed    


  125. HELBIG DR, Abu-Zeinah G, Bhavsar E, Christos PJ, et al
    Outcomes in CLL patients with NOTCH1 regulatory pathway mutations.
    Am J Hematol. 2021;96:E187-E189.
    PubMed    


    May 2021
  126. AL-SAWAF O, Gentile B, Devine J, Zhang C, et al
    Health-related quality of life with fixed-duration venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: Results from the randomized, phase 3 CLL14 trial.
    Am J Hematol. 2021 May 29. doi: 10.1002/ajh.26260.
    PubMed     Abstract available


  127. PICIOCCHI A, Messina M, Elia L, Vitale A, et al
    Prognostic impact of KMT2A-AFF1-positivity in 926 BCR-ABL1-negative B-lineage Acute Lymphoblastic Leukemia patients treated in GIMEMA clinical trials since 1996.
    Am J Hematol. 2021 May 28. doi: 10.1002/ajh.26253.
    PubMed    


  128. ST MARTIN EC, Ferrer A, Wudhikarn K, Mangaonkar A, et al
    Clinical features and survival outcomes in patients with chronic myelomonocytic leukemia arising in the context of germline predisposition syndromes.
    Am J Hematol. 2021 May 24. doi: 10.1002/ajh.26250.
    PubMed    


  129. MOULIN C, Guillemin F, Remen T, Bouclet F, et al
    Clinical, biological, and molecular genetic features of Richter syndrome and prognostic significance: a study of the French Innovative Leukemia Organization.
    Am J Hematol. 2021 May 17. doi: 10.1002/ajh.26239.
    PubMed    


  130. JAIN N, Maiti A, Ravandi F, Konopleva M, et al
    Inotuzumab Ozogamicin with Bosutinib for Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Lymphoid Blast Phase of Chronic Myeloid Leukemia.
    Am J Hematol. 2021 May 15. doi: 10.1002/ajh.26238.
    PubMed     Abstract available


  131. MORABITO F, Del Poeta G, Mauro FR, Reda G, et al
    TP53 disruption as a risk factor in the era of targeted therapies: a multicenter retrospective study of 525 chronic lymphocytic leukemia cases.
    Am J Hematol. 2021 May 14. doi: 10.1002/ajh.26235.
    PubMed    


  132. HALL KH, Brooks A, Waller EK
    Overcoming TKI resistance in a patient with chronic myeloid leukemia using combination BCR-ABL inhibition with asciminib and bosutinib.
    Am J Hematol. 2021 May 10. doi: 10.1002/ajh.26231.
    PubMed    


  133. MORABITO F, Tripepi G, Del Poeta G, Mauro FR, et al
    Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study.
    Am J Hematol. 2021;96:E168-E171.
    PubMed    


  134. OTHMAN TA, Mei M, Zhang J, Aldoss I, et al
    Rebound thrombocytosis is associated with response in AML patients treated with venetoclax and hypomethylating agents.
    Am J Hematol. 2021;96:E140-E143.
    PubMed    


    April 2021
  135. KADIA TM, Ravandi F, Borthakur G, Konopleva M, et al
    Long-term Results of Low-intensity Chemotherapy with Clofarabine or Cladribine Combined with Low-Dose Cytarabine Alternating with Decitabine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia.
    Am J Hematol. 2021 Apr 26. doi: 10.1002/ajh.26206.
    PubMed     Abstract available


  136. YILMAZ M, Daver N, Borthakur G, Kadia T, et al
    FLT3 inhibitor based induction and allogeneic stem cell transplant in complete remission 1 improve outcomes in patients with newly diagnosed Acute Myeloid Leukemia with very low FLT3 allelic burden.
    Am J Hematol. 2021 Apr 23. doi: 10.1002/ajh.26202.
    PubMed    


  137. MORABITO F, Tripepi G, Del Poeta G, Mauro FR, et al
    Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine. Results of study on 486 cases outside clinical trials.
    Am J Hematol. 2021 Apr 20. doi: 10.1002/ajh.26201.
    PubMed    


  138. JAMY O, Godby R, Sarmad R, Costa LJ, et al
    Survival of Chronic Myeloid Leukemia Patients in Comparison to the General Population in the Tyrosine Kinase Inhibitors Era: A US Population Based Study.
    Am J Hematol. 2021 Apr 17. doi: 10.1002/ajh.26195.
    PubMed    


  139. PELLAND-MARCOTTE MC, Kulkarni K, Athale UH, Pole JD, et al
    Thrombosis is associated with worse survival in children with acute lymphoblastic leukemia: a report from CYP-C.
    Am J Hematol. 2021 Apr 13. doi: 10.1002/ajh.26193.
    PubMed     Abstract available


  140. APEL A, Moshe Y, Ofran Y, Gural A, et al
    Venetoclax combinations induce high response rates in newly diagnosed Acute Myeloid Leukemia patients ineligible for intensive chemotherapy in routine practice.
    Am J Hematol. 2021 Apr 9. doi: 10.1002/ajh.26190.
    PubMed     Abstract available


  141. DONG N, Castillo Tokumori F, Isenalumhe L, Zhang Y, et al
    Large Granular Lymphocytic Leukemia - a Retrospective Study of 319 Cases.
    Am J Hematol. 2021 Apr 5. doi: 10.1002/ajh.26183.
    PubMed     Abstract available


  142. GANGAT N, Szuber N, Jawaid T, Hanson CA, et al
    Young platelet millionaires with essential thrombocythemia.
    Am J Hematol. 2021;96:E93-E95.
    PubMed    


  143. PARDANANI A
    Systemic mastocytosis in adults: 2021 Update on diagnosis, risk stratification and management.
    Am J Hematol. 2021;96:508-525.
    PubMed     Abstract available


    April 2020
  144. OHANIAN M, Telouk P, Kornblau S, Albarede F, et al
    A heavy metal baseline score predicts outcome in acute myeloid leukemia.
    Am J Hematol. 2020;95:422-434.
    PubMed     Abstract available


  145. COLTRO G, Antelo G, Lasho TL, Finke CM, et al
    Phenotypic correlates and prognostic outcomes of TET2 mutations in myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: A comprehensive study of 504 adult patients.
    Am J Hematol. 2020;95:E86-E89.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: